Citadel Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Citadel Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,000	Closed	-$7.99K	–	15958
2022 Q4	$7.99K	Sell	8,000 -32,000	-80%	-$43.1K	﹤0.01%	13778
2022 Q3	$72K	Sell	40,000 -4,500	-10%	-$13K	﹤0.01%	11365
2022 Q2	$129K	Buy	44,500 +22,000	+98%	+$54.3K	﹤0.01%	11147
2022 Q1	$62K	Sell	22,500 -25,300	-53%	-$79.6K	﹤0.01%	12661
2021 Q4	$223K	Sell	47,800 -46,900	-50%	-$293K	﹤0.01%	11628
2021 Q3	$806K	Buy	94,700 +16,000	+20%	+$226K	﹤0.01%	8688
2021 Q2	$1.29M	Buy	78,700 +35,300	+81%	+$713K	﹤0.01%	7681
2021 Q1	$958K	Buy	43,400 +5,900	+16%	+$161K	﹤0.01%	8233
2020 Q4	$1.16M	Buy	37,500 +9,300	+33%	+$235K	﹤0.01%	6488
2020 Q3	$573K	Buy	+28,200	New	+$495K	﹤0.01%	7051

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors's TCRR Position: Q1 2023 in Review

Citadel Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 233,876 shares — an estimated $234K sold.

Citadel Advisors first reported a position in TCRR in Q1 2020 and held it in 11 quarters. The position peaked at $33.6M in Q4 2020. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

Citadel Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 233,876 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $234K.
Citadel Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Citadel Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $33.6M in Q4 2020.
59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.